@article{3077072,
    title = "Ixazomib-lenalidomide-dexamethasone in routine clinical practice: Effectiveness in relapsed/refractory multiple myeloma",
    author = "Hájek, R. and Minarík, J. and Straub, J. and Pour, L. and Jungova, A. and Berdeja, J.G. and Boccadoro, M. and Brozova, L. and Spencer, A. and Van Rhee, F. and Vela-Ojeda, J. and Thompson, M.A. and Abonour, R. and Chari, A. and Cook, G. and Costello, C.L. and Davies, F.E. and Hungria, V.T.M. and Lee, H.C. and Leleu, X. and Puig, N. and Rifkin, R.M. and Terpos, E. and Usmani, S.Z. and Weisel, K.C. and Zonder, J.A. and Barinová, M. and Kuhn, M. and Šilar, J. and Cápková, L. and Galvez, K. and Lu, J. and Elliott, J. and Stull, D.M. and Ren, K. and Maisnar, V.",
    journal = "Future Oncology",
    year = "2021",
    volume = "17",
    number = "19",
    pages = "2499-2512",
    publisher = "Future Medicine Ltd",
    issn = "1479-6694, 1744-8301",
    doi = "10.2217/fon-2020-1225",
    keywords = "dexamethasone;  ixazomib;  lenalidomide;  antineoplastic agent;  boron derivative;  dexamethasone;  glycine;  ixazomib;  lenalidomide, adult;  aged;  Article;  cancer recurrence;  clinical outcome;  clinical practice;  controlled study;  data analysis;  data integration;  diarrhea;  drug dose reduction;  drug efficacy;  drug response;  drug safety;  drug withdrawal;  fatigue;  female;  follow up;  human;  infection;  major clinical study;  male;  middle aged;  multiple myeloma;  neuropathy;  neutropenia;  observational study;  overall response rate;  progression free survival;  thrombocytopenia;  time to treatment;  clinical trial;  drug resistance;  mortality;  multicenter study;  multiple myeloma;  pathology;  prospective study;  tumor recurrence;  very elderly, Adult;  Aged;  Aged, 80 and over;  Antineoplastic Combined Chemotherapy Protocols;  Boron Compounds;  Dexamethasone;  Drug Resistance, Neoplasm;  Female;  Glycine;  Humans;  Lenalidomide;  Male;  Middle Aged;  Multiple Myeloma;  Neoplasm Recurrence, Local;  Progression-Free Survival;  Prospective Studies",
    abstract = "Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1. Clinical trial registration: NCT02761187 (ClinicalTrials.gov)</ext-link. © 2021 Future Medicine Ltd.. All rights reserved."
}